If PTAB Backs Berkeley IP Holders' New Patent Claims, CRISPR Licensing Could Be Simplified
Executive Summary
The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.